Repurposing Axl Kinase Inhibitors for the Treatment of Respiratory Syncytial Virus Infection-Reference-Cited by-同舟云学术

Repurposing Axl Kinase Inhibitors for the Treatment of Respiratory Syncytial Virus Infection

Published:2023-02-28 Issue: Volume: Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Zhang Dan¹²,Zhao Yuanhui¹²³,You Xiaoxin²,He Susu¹²³^ORCID,Li Erguang¹²⁴⁵^ORCID

Affiliation:

1. State Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing, China

2. Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing, Jiangsu, China

3. Yancheng Medical Research Center, The Affiliated Yancheng People's 1st Hospital of Nanjing University Medical School, Yancheng, Jiangsu, China

4. Institute of Medical Virology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China

5. Shenzhen Research Institute of Nanjing University, Shenzhen, China

Abstract

Respiratory syncytial virus (RSV) infection persists as a common pathogen of pulmonary infection in infants and in the elderly with high morbidity and mortality. However, no specific therapeutics are available.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Jiangsu Province

Central Universities Fundamental Research Fund

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01487-22

Reference70 articles.

1. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study

2. Association of Age at First Severe Respiratory Syncytial Virus Disease With Subsequent Risk of Severe Asthma: A Population-Based Cohort Study

3. Global Disease Burden Estimates of Respiratory Syncytial Virus–Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis

4. Innate Type 2 Responses to Respiratory Syncytial Virus Infection

5. Palivizumab epitope–displaying virus-like particles protect rodents from RSV challenge

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Progress toward the Discovery of Small Molecules as Novel Anti-Respiratory Syncytial Virus Agents;Journal of Medicinal Chemistry;2024-07-06